Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials

Transaction summary

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($25.37); post-transaction worth based connected April 29, 2026, marketplace adjacent ($25.68).

Key questions

• How does this transaction impact Dandekar's ongoing vulnerability to Maze Therapeutics?
  Dandekar's nonstop communal banal holdings were reduced by 41.66%, but helium maintains 44,143 banal options that tin beryllium exercised for aboriginal equity vulnerability oregon liquidity events.

• What was the quality of the shares disposed successful this filing?
  All 7,500 shares were acquired via enactment workout and instantly sold successful the unfastened market, reflecting a derivative-driven liquidity lawsuit alternatively than a discretionary open-market sale.

• Does this merchantability correspond a alteration successful Dandekar's trading cadence?
  The 7,500-share lawsuit is accordant with anterior administrative transactions successful 2026, with declining commercialized sizes explained by the reduced disposable stock number aft anterior exercises and sales.

• What are the implications for aboriginal insider activity?
  While nonstop holdings are present modest, the sizable remaining enactment presumption provides capableness for further akin transactions, supporting ongoing liquidity scheduling nether the existing Rule 10b5-1 plan.

Company overview

1-year terms alteration calculated utilizing April 29, 2026, arsenic the notation date.

Company snapshot

• Develops tiny molecule precision medicines targeting renal, cardiovascular, metabolic diseases, and obesity, with pb programs MZE829 (APOL1 inhibitor, signifier 2) and MZE782 (SLC6A19 inhibitor, signifier 1).

• Operates a clinical-stage biopharmaceutical exemplary focused connected advancing proprietary cause candidates done early- and mid-stage objective trials.

• Develops small-molecule precision medicines for renal and metabolic diseases successful the United States.

Maze Therapeutics, Inc. is simply a clinical-stage biotechnology institution leveraging familial insights to make targeted therapies for analyzable renal and metabolic diseases. The company’s strategy centers connected advancing a focused pipeline of oral small-molecule drugs with the imaginable to code important unmet aesculapian needs. With a thin workforce and a beardown accent connected precision medicine, Maze Therapeutics seeks to differentiate itself done innovation and a data-driven attack to cause development.